The Janssen Portfolio of Long-Acting Injections
Featuring INVEGA SUSTENNA®, INVEGA TRINZA®, and the only 6-month schizophrenia injection,
What long-acting treatments can offer
You didn’t choose to live with schizophrenia, but you have a choice in how you manage it. It’s important to talk with your healthcare professional and learn about all the treatment options available to you, like a long-term approach to treatment with INVEGA SUSTENNA® (1-month paliperidone palmitate), INVEGA TRINZA® (3-month paliperidone palmitate), or newly approved INVEGA HAFYERATM (6-month paliperidone palmitate) from the Janssen portfolio of long-acting injections (LAIs).
Treatment with LAIs can help you feel confident that the medication you need is in your system for a month,* 3 months,† or 6 months‡ with a single dose. LAIs can also help control schizophrenia symptoms in adults and help delay another episode.
In a pivotal long-term study, 90% of adult patients taking INVEGA SUSTENNA® did not experience a significant return of schizophrenia symptoms vs 66% of those not treated.
In a separate pivotal long-term study, 93% of adult patients taking INVEGA TRINZA® did not experience a significant return of schizophrenia symptoms vs 77% of those not treated.
A long-term, global clinical study was conducted to show whether INVEGA HAFYERATM was as effective as INVEGA TRINZA® in symptom control with similar safety and side effects. In this study, 92.5% of patients treated with INVEGA HAFYERATM and 95% of patients treated with INVEGA TRINZA® did not experience an episode at 12 months.
The Janssen portfolio of LAIs has 3 treatment options with the same active ingredient, designed to be gradually released to help control schizophrenia symptoms and delay time to another relapse in adults.
INVEGA SUSTENNA® is given once a month after 2 starting doses.
*After receiving 2 starting doses when treating with INVEGA SUSTENNA®.
† When treating with INVEGA TRINZA® after being adequately treated with INVEGA SUSTENNA® for at least 4 months.
‡ When treating with INVEGA HAFYERATM after being adequately treated with INVEGA SUSTENNA® for at least 4 months or INVEGA TRINZA® for one 3-month cycle.
* Elizabeth is a volunteer with the SHARE Network, a volunteer program dedicated to helping adults living with schizophrenia share their personal health stories.
Real advice from
Do not receive INVEGA HAFYERATM, INVEGA TRINZA® or INVEGA SUSTENNA® if you are allergic to paliperidone, paliperidone palmitate, risperidone, or any of the ingredients in INVEGA HAFYERATM, INVEGA TRINZA® or INVEGA SUSTENNA®. See the end of the Patient Information leaflet in the full Prescribing Information for a complete list of INVEGA HAFYERATM, INVEGA TRINZA® and INVEGA SUSTENNA® ingredients.
As with any medicine, INVEGA SUSTENNA®, INVEGA TRINZA®, and INVEGA HAFYERATM may cause side effects in some people, so the risks are important to consider as you and your healthcare professional make decisions about your treatment.
The most common side effects for INVEGA SUSTENNA® include: injection site reactions, sleepiness or drowsiness, dizziness, feeling of inner restlessness or needing to be constantly moving, and abnormal muscle movements, including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes.
The most common side effects of INVEGA TRINZA® include: injection site reactions, weight gain, headache, upper respiratory tract infections, feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness and shuffling walk.
The most common side effects of INVEGA HAFYERATM include: upper respiratory tract infections, injection site reactions, weight gain, headache, and movement disorders including feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness, and shuffling walk.
Tell your Treatment Team if you have any side effect that bothers you or does not go away.